N/A N=151 Stress Management and Biomarkers of Risk in Cardiac Rehabilitation
Coronary Heart Disease
Primary: Absolute Composite Stress Score — 77.6; 67.5 Mean rank score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=130 A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Leukemia
Primary: Major Cytogenetic Response (MCyR) Rate — 89.7 percentage of participants
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 2 N=68 Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
Breast Cancer
Primary: Change in Bone Mineral Density (BMD) From Baseline to 1 Year — 0.048; 0.007; 0.014; 0.005 grams per cubic centimeter
Phase 4 N=90 The Effects of Scalp Block With Bupivacaine Versus Levobupivacaine
Hypertension
Primary: Change in Mean Arterial Pressure — 110; 105; 100 mmHg
Phase 3 N=1,113 A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
Asthma
Primary: Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) ) — 0.056…
Phase 4 N=11,729 A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)
Asthma
Primary: Time-to-First Serious Asthma Outcomes (SAO): Number of First SAO in the MF/F vs MF Arms — 39; 32 Serious asthma outcomes — p=0.411
N/A N=49 Study for Using Radiosurgery on Limited Metastases of Breast Cancer
Breast Cancer, Metastatic
Primary: Overall Survival — 74 percentage of participants
Phase 3 N=49 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
Chronic Thrombocytopenia · Immune Thrombocytopenia
Primary: Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period — 0; 12.4 Weeks — p=<0.0001
N/A N=1,108 Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)
Femoral Neck Fractures
Primary: Revision Surgery — 107; 117 Participants
Phase 2 N=90 Sitagliptin for Reducing Inflammation and Immune Activation
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 15/16 — -0.03; -0.03 log10 pg/mL — p=1.000
Phase 2 N=3,013 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
Virus Diseases
Primary: Number of Subjects With Solicited Local Adverse Events — 356; 57; 3; 0 Participants
Phase 4 N=15 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale — 18.9; 7.5 units on a scale
N/A N=48 Manual Cervical Distraction: Measuring Chiropractic Delivery for Neck Pain Clinical Trial
Neck Pain · Pain in Arm, Unspecified
Primary: Range of Traction Forces — 13.82; 38.3; 65.08; 17.19 Newtons (N)
Phase 2 N=319 Bay98-7196, Dose Finding / POC Study
Endometriosis
Primary: Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days…